

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
0975.1005-006APPLICATION NO.  
09/756,398INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

July 3, 2001

(See several sheets if necessary)

APPLICANT  
Junming Le, et al.FILING DATE  
January 8, 2001GROUP  
1642

RECEIVED

JUL 12 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRI- ATE
KAL	AA	4,603,106	07/29/86	Cerami et al.	435	7	
	AB	4,822,776	04/18/89	Cerami et al.	514	21	
	AC	5,658,570	08/19/97	Newman et al.	424	184.1	
	AD	5,750,105	5/12/98	Newman et al.	424	133.1	
✓	AE	5,231,024	7/27/93	Moeller et al.	435	240.27	
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI ON YES NO
KAL	AL	0212489A2	04 MAR 87	EPO			
	AM	0218868A2	22 APR 87	EPO			
	AN	0288088A2	26 OCT 88	EPO			
	AO	0308378A2	22 MAR 89	EPO			
	AP	0380068A1	01 AUG 90	EPO			
✓	AQ	0393438A3	24 OCT 90	EPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," Nature, 316:552-554 (1985).
	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, 229:869-871 (1985).
✓	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229:1202-1207 (1985).

EXAMINER

Karin G. Canella

DATE CONSIDERED

4/14/04

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
0975.1005-006APPLICATION NO.  
09/756,398INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONAPPLICANT  
Junming Le, et al.FILING DATE  
January 8, 2001GROUP  
1642

JUL 12 2001

TECH CENTER 1600/2900

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
-------------------------------	-----------------	------	------	-------	---------------	----------------------------------

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL2 0398327A1	22 NOV 90	EPO			
	AM2 0412486A1	13 FEB 91	EPO			
	AN2 0433900A1	26 JUN 91	EPO			
	AO2 0526905A2	10 FEB 93	EPO			
	AP2 WO91/02078	21 FEB 91	PCT			
✓	AQ2 WO92/07076	30 APR 92	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 137(2):847-854 (1986).
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987).
	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987).
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987).
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987).
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).
	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).
✓	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).

EXAMINER

DATE CONSIDERED

Karen A. Gammella

4/14/04

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
0975.1005-006APPLICATION NO.  
09/756,398INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONAPPLICANT  
Junming Le, et al.

RECEIVED

JUL 09 2001

July 3, 2001

FILING DATE  
January 8, 2001GROUP  
1642

JUL 12 2001

(Indicate several sheets if necessary)

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL3 WO92/13095	06 AUG 92	PCT			
	AM3 0260610A2	23 MAR 88	EPO			
	AN3 91/09967	11 JUL 91	PCT			
	AO3 0351789A2	24 JAN 90	EPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).
	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i> .
	AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989).
	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor $\alpha$ /Cachectin and Murine Interleukin 1 $\alpha$ Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989).
	AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989).
	AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).

EXAMINER

Karen A. Ganello

DATE CONSIDERED

4/14/01

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-006		APPLICATION NO. 09/756,398			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 3, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.		RECEIVED JUL 12 2001 TECH CENTER 1600/2900			
		FILING DATE January 8, 2001				GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAL	AP3	0350690A2	17 JAN 90	EPO			
	AQ3	90/00902	08 FEB 90	PCT			
	AL4	WO 92/11383	09 JUL92	PCT			
	AM4	WO 93/02108	4 FEB 93	PCT			
✓	AN4	WO 92/16553	19-MAR 92	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAL	AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor. Reduce Interleukin 1 $\beta$ and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).					
	AS3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- $\alpha$ ) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).					
	AT3	Herve, P. et al., "Monoclonal Anti TNF $\alpha$ Antibody for the Treatment of Severe Acute GVHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990).					
	AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- $\alpha$ in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990).					
	AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990).					
	AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990).					
	AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- $\alpha$ monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990).					
✓	AY3	Hinshaw, L.B. et al., "Survival of Primates in LD <sub>100</sub> Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF $\alpha$ )," <i>Circulatory Shock</i> , 30:279-292 (1990).					
EXAMINER		DATE CONSIDERED					
Karen A. Gault		4/19/04					

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-006		APPLICATION NO. 09/756,398			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 3, 2001 (attach several sheets if necessary)		APPLICANT Junming Le, et al.		RECEIVED JUL 12 2001 TECH CENTER 1600/2900			
		FILING DATE January 8, 2001				GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC	AZ3	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).					
	AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).					
	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).					
	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).					
	AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).					
	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E <sub>2</sub> Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor $\alpha$ ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).					
	AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).					
	AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor $\alpha$ : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).					
✓	AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).					
EXAMINER		DATE CONSIDERED					
Karin A. Ganello		4/14/04					

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
0975.1005-006APPLICATION NO.  
09/756,398INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

July 3, 2001

(See several sheets if necessary)

APPLICANT  
Junming Le, et al.FILING DATE  
January 8, 2001GROUP  
1642

RECEIVED

JUL 12 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	A24	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991).
	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).
	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992).
	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992).
	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993).
	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993).
	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985).
	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985).
	AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990).
✓	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia &amp; Sepsis Conference</i> (1991).

EXAMINER

DATE CONSIDERED

James A. Garella

7/14/01

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
0975.1005-006APPLICATION NO.  
09/756,398INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

JUL 09 2001

July 3, 2001

(Use several sheets if necessary)

APPLICANT  
Junming Le, et al.FILING DATE  
January 8, 2001GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, Endotoxemia & Sepsis Conference (1991).
AS6	Genebank Accession, No. N90300 (1989, November 1).
AT6	Genebank Accession, No. M32046 (1990, June 15).
AU6	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", Behring Inst. Mitt, No.78:118-132 (1985).

EXAMINER

DATE CONSIDERED

Karen A. Connelley

9/14/04